Factor Bioscience to Present Innovative Approaches to Treating Solid Tumors at ISSCR 2025 Annual Meeting
In an exciting development for cancer treatment, Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, MA, is set to showcase its groundbreaking iMacrophage technology at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting in Hong Kong, scheduled between June 11 and 14, 2025. The company is excited to present three key studies that highlight the latest advancements in their engineered iMacrophage program, known as FACT-112. This innovative therapy specifically targets solid tumors, marking a significant milestone in cancer therapy.
The highlight of the presentations will be data demonstrating the effective delivery of IL-12, an important immunomodulatory cytokine recognized for its anti-tumor properties. Dr. Matt Angel, the Co-Founder, Chairman, and CEO of Factor, expressed enthusiasm about the findings, stating that this first-ever demonstration of targeted delivery via engineered macrophages could pave the way for new cancer treatment options. The ability to deliver such powerful cytokines directly into the tumor microenvironment is a game-changer in the fight against cancer, especially for challenging cases like platinum-resistant ovarian cancers.
Dr. Kyle Garland, the Director of Translational Science at Factor, emphasized the decade-long commitment to developing cutting-edge RNA-based technologies that now allows the company to innovate cancer therapies effectively. According to him, the data shared will reveal significant advancements in how genetic engineering is being utilized to create therapies that can directly combat cancer.
The specifics of the presentations at ISSCR include:
Factor Bioscience, founded in 2011, focuses on leveraging its patented gene editing platform for life-saving cell and gene therapies. Their commitment is to bring innovative solutions to patients suffering from a wide range of diseases, with a pronounced focus on cancer treatments. More details about ISSCR 2025 can be found on their official website, which illustrates the significant impact that advancements in stem cell research can have on future medical therapies. For additional information on Factor Bioscience and its pioneering research, you can visit their website at www.factorbio.com.
This year's ISSCR Annual Meeting serves as a vital platform for scientific exchange, bringing together researchers and professionals from around the globe to discuss cutting-edge developments in stem cell research, signaling a hopeful future in treating life-threatening diseases. Through presentations like those from Factor Bioscience, the intricate link between science and medicine continues to unravel, showcasing how innovative technologies can potentially save lives.
The highlight of the presentations will be data demonstrating the effective delivery of IL-12, an important immunomodulatory cytokine recognized for its anti-tumor properties. Dr. Matt Angel, the Co-Founder, Chairman, and CEO of Factor, expressed enthusiasm about the findings, stating that this first-ever demonstration of targeted delivery via engineered macrophages could pave the way for new cancer treatment options. The ability to deliver such powerful cytokines directly into the tumor microenvironment is a game-changer in the fight against cancer, especially for challenging cases like platinum-resistant ovarian cancers.
Dr. Kyle Garland, the Director of Translational Science at Factor, emphasized the decade-long commitment to developing cutting-edge RNA-based technologies that now allows the company to innovate cancer therapies effectively. According to him, the data shared will reveal significant advancements in how genetic engineering is being utilized to create therapies that can directly combat cancer.
The specifics of the presentations at ISSCR include:
- - Hypoimmune iPSC-derived Macrophages Engineered to Express IL-12 Activate Lymphocytes Against Platinum-Resistant Ovarian Cancer - Ian Hay will present this study on June 13, focused on the therapeutic potential of using modified iPSCs (induced pluripotent stem cells) to target difficult-to-treat cancers.
- - UltraSlice™ mRNA Incorporating 5-Methoxyuridine Efficiently Inserts Transgene Sequences in iPSCs with High Viability and Mitigates dsRNA Production - Presented by Cassandra Ng on June 12, this study highlights the efficacy of the UltraSlice™ technology in generating high-viability iPSCs while minimizing unwanted side effects.
- - Directed Differentiation of mRNA-Reprogrammed iPSCs via Bioreactors Generates Clinically Relevant Yields of Neural Stem and Progenitor Cells that can be Engineered to Secrete Therapeutic Proteins - Claire Aibel’s presentation on June 13 will showcase production techniques for neural cells that can potentially offer new therapeutic strategies for various neurological conditions.
Factor Bioscience, founded in 2011, focuses on leveraging its patented gene editing platform for life-saving cell and gene therapies. Their commitment is to bring innovative solutions to patients suffering from a wide range of diseases, with a pronounced focus on cancer treatments. More details about ISSCR 2025 can be found on their official website, which illustrates the significant impact that advancements in stem cell research can have on future medical therapies. For additional information on Factor Bioscience and its pioneering research, you can visit their website at www.factorbio.com.
This year's ISSCR Annual Meeting serves as a vital platform for scientific exchange, bringing together researchers and professionals from around the globe to discuss cutting-edge developments in stem cell research, signaling a hopeful future in treating life-threatening diseases. Through presentations like those from Factor Bioscience, the intricate link between science and medicine continues to unravel, showcasing how innovative technologies can potentially save lives.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.